$7.94
1.85% yesterday
Nasdaq, Jul 03, 09:47 pm CET
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Travere Therapeutics Inc Share price

$7.94
+0.22 2.85% 1M
-1.16 12.75% 6M
-1.05 11.68% YTD
-7.61 48.94% 1Y
-7.38 48.17% 3Y
-13.06 62.19% 5Y
-4.88 38.07% 10Y
Nasdaq, Closing price Wed, Jul 03 2024
-0.15 1.85%
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Key metrics

Market capitalization $604.46m
Enterprise Value $567.44m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.10
P/S ratio (TTM) P/S ratio 3.30
P/B ratio (TTM) P/B ratio 8.16
Sales growth (TTM) Sales growth -16.91%
Turnover (TTM) Turnover $183.23m
EBIT (operating result TTM) EBIT $-334.94m
Free cash flow (TTM) Free cash flow $-317.95m
Cash position $441.04m
EPS (TTM) EPS $-5.06
P/E ratio expected negative
P/S ratio expected 2.81
EV/Sales expected 2.64
Short interest 19.83%
Show more

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.

Travere Therapeutics Inc Share analysis

Unlock Scores for Free

Analyst opinions

16 Analysts have issued a Travere Therapeutics Inc forecast:

11x Buy
69%
5x Hold
31%

Analyst opinions

16 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
69%
Hold
31%

Financial data from Travere Therapeutics Inc

Assets
Mar '24
481 481
Cash position 441 441
Claims 27 27
Inventories 4.53 4.53
Other current assets Other current assets Current assets 8.97 8.97
182 182
Property, plant and equipment 24 24
Financial assets - -
Intangible assets 101 101
Other fixed assets Other assets Fixed assets 57 57
Total assets 664 664
Liabilities
Mar '24
Equity 74 74
589 589
Current liabilities 173 173
Non-current liabilities 416 416
Total capital 664 664

Figures in millions USD.

Don't miss a thing! We will send you all news about the Travere Therapeutics Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Travere Therapeutics Inc Share News

Neutral
GlobeNewsWire
22 days ago
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 10,500 shares of its common stock. These inducement RSUs are subject to the t...
Neutral
GlobeNewsWire
about 2 months ago
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,500 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and ind...
Neutral
GlobeNewsWire
about 2 months ago
Presentations highlight data supporting FILSPARI ® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN
More Travere Therapeutics Inc News

Company profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 380
Founded 2008
Website www.travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today